← All trials
NCT05680584
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2023
- Primary completion
- Jan 30, 2024
- Completion date
- Jan 30, 2024
- First posted
- Jan 11, 2023
- Last posted
- Dec 27, 2023
- Enrollment
- 78
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Minia UniversityLead sponsor
- Minia UniversityReponsible party - principal investigator
- Minia UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.